Compare Invesco DB Agriculture Fund (DBA) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Agriculture Fund vs Viatris Inc — how do they compare? Invesco DB Agriculture Fund trades at $27.59, while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc pays a 2.95% dividend while Invesco DB Agriculture Fund pays none, and Viatris Inc is trading nearer its 52-week high, Invesco DB Agriculture Fund nearer its low. Which is the better fit depends on your goals.
| DBA | VTRS | |
|---|---|---|
52-Week High | $28.73 | $17.86 |
52-Week Low | $25.44 | $9.49 |
Market Cap | — | $18.69B |
Sector | — | Health |
Enterprise Value | — | $30.81B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBA, the Invesco DB Agriculture Fund ETF, trades at $27.62, up 0.69% today, and has shown strong performance with a 5% gain over the past month, outperforming the S&P 500. The technical outlook is bullish based on moving averages, while oscillators are neutral. Recent news highlights agricultural commodity strength, with DBA consolidating near highs amid a bullish trend since 2020, supported by a 3.25% yield and diversified futures exposure.
The outlook for DBA remains positive due to favorable agricultural market conditions and geopolitical factors driving commodity prices. Key risks include sector volatility and management fees. Analyst sentiment is constructive, viewing the ETF as a play on rising agricultural demand, though investors should monitor commodity price fluctuations and global supply chain disruptions.
Viatris (VTRS) trades at $16.43, up 0.86% with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, with revenues rising 5% year-over-year. However, fundamental challenges persist with negative net income margin (-2.79%) and elevated P/E ratio (236.2). Recent developments include FDA approval for Gwyn Lo contraceptive patch and strategic divestitures to sharpen focus.
While Viatris shows operational improvements with consistent cash flow generation, the stock faces headwinds from profitability challenges and high valuation multiples. The mixed analyst sentiment (30.77% buy rating) reflects uncertainty about the company's turnaround trajectory. Key risks include ongoing margin pressure and competitive threats in the generic pharmaceutical space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
